about
Impact of treatment with rosuvastatin and atorvastatin on cardiovascular outcomes: evidence from the Archimedes-simulated clinical trialsValidation of population-based disease simulation models: a review of concepts and methodsValidation and calibration of structural models that combine information from multiple sources.GetReal in mathematical modelling: a review of studies predicting drug effectiveness in the real world.In silico design of optimal ratio for co-administration of pramlintide and insulin in type 1 diabetes.In silico Models of Alcohol Dependence and TreatmentImpact of blood glucose self-monitoring errors on glucose variability, risk for hypoglycemia, and average glucose control in type 1 diabetes: an in silico study.Simulation environment to evaluate closed-loop insulin delivery systems in type 1 diabetes.Diabetes: Models, Signals, and Control.In silico preclinical trials: a proof of concept in closed-loop control of type 1 diabetes.Setting a fair performance standard for physicians' quality of patient careConceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--2.Bioregulatory systems medicine: an innovative approach to integrating the science of molecular networks, inflammation, and systems biology with the patient's autoregulatory capacity?A critical review of mathematical models and data used in diabetology.Improvements in ability to detect undiagnosed diabetes by using information on family history among adults in the United StatesChronic disease modeling and simulation software.Validation of the IHE Cohort Model of Type 2 Diabetes and the impact of choice of macrovascular risk equationsValidation of a model to investigate the effects of modifying cardiovascular disease (CVD) risk factors on the burden of CVD: the rotterdam ischemic heart disease and stroke computer simulation (RISC) model.A standardized vascular disease health check in europe: a cost-effectiveness analysis.A population-based risk algorithm for the development of diabetes: development and validation of the Diabetes Population Risk Tool (DPoRT).Validating a dimensionless number for glucose homeostasis in humansClinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease.Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis.Impact of comorbidity on colorectal cancer screening cost-effectiveness study in diabetic populations.The role of ethnicity in predicting diabetes risk at the population levelThe impact of initial statin treatment decisions on cardiovascular outcomes in clinical care settings: estimates using the Archimedes Model.A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategies.Exenatide extended-release; clinical trials, patient preference, and economic considerations.The impact of prevention on reducing the burden of cardiovascular diseaseRelationship of insulin resistance and related metabolic variables to coronary artery disease: a mathematical analysisThe metabolic syndrome and cardiovascular risk: implications for clinical practice.Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population.Use of IndiGO individualized clinical guidelines in primary care.A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus.Description of a New Predictive Modeling Approach That Correlates the Risk and Associated Cost of Well-Defined Diabetes-Related Complications With Changes in Glycated Hemoglobin (HbA1c).Delays in treatment intensification with oral antidiabetic drugs and risk of microvascular and macrovascular events in patients with poor glycaemic control: An individual patient simulation study.Methods for Building and Validating Equations for Physiology-Based Mathematical Models: Glucose Metabolism and Type 2 Diabetes in the Archimedes Model.Why Do Health Economists Promote Technology Adoption Rather Than the Search for Efficiency? A Proposal for a Change in Our Approach to Economic Evaluation in Health Care.Projection of osteoporosis-related fractures and costs in China: 2010-2050.Screening for and treatment of osteoporosis: construction and validation of a state-transition microsimulation cost-effectiveness model.
P2860
Q26776293-A018D756-EACE-4AE9-AB15-BD769BF1B80FQ28744274-49711698-6E2A-45E5-A167-F0FEC456B5FAQ30239838-0A28A5CC-D818-46FC-B4E6-D4ECAD368F20Q30248472-273F9A1C-C684-4DA8-B605-1A06716EF624Q30410405-678E0637-7A1C-4B60-B44D-2D7418926ED1Q30428337-918BD77C-5F7E-4AD3-9DDB-6F953C09047BQ30432525-60303A42-6B06-4FD2-BA2F-D89A39405653Q30433675-EE978DC9-52B1-4FBD-A9DE-8FD350A50088Q30434551-7A1C946D-D7E8-4062-8D20-BEC08CACEA67Q30439654-186C5EFD-FC22-4DF8-9F8B-7B39ABC4E5EDQ30499654-164B379C-96A2-4C4A-8A64-8E186AA085A8Q30595581-F802F29B-7884-4E7E-B082-8F8105CE3EAAQ30661665-8B0D46A6-3750-4998-B277-1AD0A9AEAAFCQ31047512-618835AD-21E3-4A0D-A953-08861CB8C9CDQ33838068-919C2D62-FF06-48E1-AFBA-82F918A3F754Q34108081-2AADDC01-6E1A-4DC2-A977-B365C73BF1B2Q34332236-328FC401-6A7D-4597-B54F-C8CD736B44EBQ34502738-A741DBEC-4567-4D31-847F-38E6FD6E765BQ34837441-3B82D7A0-72D5-4B31-99EA-0A784AF3BDDDQ35038338-65CEE661-5459-4612-861F-70FA189E962AQ35471850-F6D2E1F8-8B43-45C8-8ADF-E7EDE4327EB1Q35717211-DEB8C472-310E-4488-8D4F-C2BD529A4F22Q35940436-FB660A6A-9180-4095-B5BF-5710EEEFA47DQ35980669-289CF8DD-7B98-400D-9283-9DFA9A6228B0Q36275871-1BD7A224-5268-479C-B9EF-FE85810908AAQ36398223-10B8771D-4EC4-4840-A0F0-305E30DAEE1FQ36519198-3A49CE44-F59E-49FC-8F1C-82F832F478E2Q36538817-13E13EB7-89FA-4D01-96A9-61E37F6CFAE7Q36807520-9C0C6D36-8682-4F25-8F1B-22079EC0E6C8Q37067169-E9C093E0-21A4-405A-B3FF-98590D535188Q37159103-FE41DAC8-787B-48DC-B1EF-13A5C160FF86Q37221783-D4199322-F811-4382-83BB-FE41A2BCEDFBQ37715378-230D988A-47DD-4ADC-BEF8-C785E36B1323Q38705217-F5D9D949-FC05-482C-8631-022D432044CCQ38924071-87DA69C2-16DE-4497-91F9-995A25C65852Q38955525-5A4923C3-0D06-49C2-ADEA-0E0F4984E673Q40454962-B32AAA30-AD3F-4F63-AD7B-930241518AEDQ40694127-AEE52D79-BAB6-4D03-A8DB-5D0CD9D751BEQ41243465-CDCA0930-047F-4424-A657-8EA293D67D3EQ41611263-A3DB3A07-8B5B-4953-85D8-7F3D92846DEA
P2860
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Validation of the archimedes diabetes model.
@en
Validation of the archimedes diabetes model.
@nl
type
label
Validation of the archimedes diabetes model.
@en
Validation of the archimedes diabetes model.
@nl
prefLabel
Validation of the archimedes diabetes model.
@en
Validation of the archimedes diabetes model.
@nl
P1433
P1476
Validation of the archimedes diabetes model.
@en
P2093
Leonard Schlessinger
P304
P356
10.2337/DIACARE.26.11.3102
P407
P577
2003-11-01T00:00:00Z